Thymosin Alpha-1 vs LL-37: Research Comparison
A Side-By-Side Research Comparison Of Thymosin Alpha-1 And LL-37 - two immune-modulating research peptides with distinct mechanisms. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Thymosin Alpha-1 | LL-37 | |
|---|---|---|
| Category | Immunity & Wellness | Immunity & Wellness |
| Compound Class | 28-amino acid peptide; N-terminal fragment of prothymosin alpha; biological response modifier | Endogenous cationic host defense peptide (cathelicidin family); 37-residue C-terminal fragment of hCAP-18 |
| Evidence Tier | Approved Drug | Research Compound |
| Molecular Target | TLR2/TLR9 signaling; dendritic cell maturation; T-helper (Th1) polarization; NK cell cytotoxicity; NF-kB immunomodulation | Bacterial membrane disruption; TLR4 and FPRL1 receptor signaling; EGFR transactivation; immunomodulatory cytokine network |
| Molecular Weight | 3108.3 Da | 4493.3 Da |
| Amino Acid Sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
| CAS Number | 62304-98-7 | 154947-66-7 |
| Half-Life | ~2 hours | ~30 minutes |
| Studied For | Chronic hepatitis B treatment, Chronic hepatitis C treatment, Cancer immune adjunct therapy, Vaccine adjuvant | Antimicrobial / antibiofilm research, Wound healing, Innate immunity modulation, Autoimmune disease research |
About Thymosin Alpha-1
A well-studied immune-modulating peptide approved abroad for hepatitis and as a cancer adjunct.
Read The Full Thymosin Alpha-1 MonographAbout LL-37
The human antimicrobial peptide, studied for infection and immunity; can also promote autoimmunity.
Read The Full LL-37 MonographKey Differences
- Evidence tier differs: Thymosin Alpha-1 is classified as Approved Drug; LL-37 is classified as Research Compound.
- Reported half-life differs: Thymosin Alpha-1 at ~2 hours versus LL-37 at ~30 minutes.
- Primary molecular target differs: Thymosin Alpha-1 acts on TLR2/TLR9 signaling; dendritic cell maturation; T-helper (Th1) polarization; NK cell cytotoxicity; NF-kB immunomodulation; LL-37 acts on Bacterial membrane disruption; TLR4 and FPRL1 receptor signaling; EGFR transactivation; immunomodulatory cytokine network.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.